Across TCGA pan-cancer cohorts, KRTAP9-9 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated KRTAP9-9 data layer compared with 11 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher KRTAP9-9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRTAP9-9 expression acts as an unfavorable survival marker.
HNSC, SKCM, and SCLC are the cancer types where KRTAP9-9 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.